Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed By Reuters
[ad_1] Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed [ad_2] Source link Illumina CFO Goswami to depart, former Summit Therapeutics exec...
JMP Securities rates Werewolf Therapeutics stock Outperform, says platform ‘inovative’ By Investing.com
[ad_1] On Wednesday, JMP Securities initiated coverage on Werewolf Therapeutics Inc. (NASDAQ:HOWL) stock with a Market Outperform rating and set a price target of $12.00....
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels By Reuters
[ad_1] (Reuters) -Verve Therapeutics said on Tuesday that it had paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol...
Earnings call: Zevra Therapeutics reports progress and financials for Q4 2023 By Investing.com
[ad_1] Zevra Therapeutics (ticker not provided) has announced key achievements and financial results for the fourth quarter of 2023. The company successfully closed the Acer...
Gyre Therapeutics appoints new board member By Investing.com
[ad_1] © Reuters. SAN DIEGO – Gyre Therapeutics (NASDAQ:GYRE), a clinical-stage biotechnology company, announced today the appointment of Rodney L. Nussbaum to its Board of...
Vera Therapeutics shares target raised by Wedbush, cites ‘ORIGIN 3’ enrollment By Investing.com
[ad_1] © Reuters. On Thursday, Wedbush maintained its Outperform rating on Vera Therapeutics (NASDAQ:VERA) and increased the shares price target to $34 from $21. The...
Aquestive Therapeutics stock target raised to $8 on FDA hopes By Investing.com
[ad_1] © Reuters. On Wednesday, Lake Street Capital Markets adjusted its outlook on Aquestive Therapeutics (NASDAQ:), a pharmaceutical company, by increasing the price target on...
JPMorgan bullish on Kyverna Therapeutics stock, sees ‘significant’ potential By Investing.com
[ad_1] © Reuters. Monday – Kyverna Therapeutics Inc (NASDAQ:KYTX) has received a new Overweight rating from JPMorgan, with the investment firm setting a price target...
Pro Research: Wall Street dives into CRISPR Therapeutics’ gene editing future By Investing.com
[ad_1] © Reuters Explore Wall Street’s expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy...
Iterum Therapeutics upgraded to Buy on successful trial By Investing.com
[ad_1] © Reuters. On Wednesday, H.C. Wainwright changed its stance on Iterum Therapeutics (NASDAQ:), moving from a Neutral rating to Buy. The firm has set...